Clifford P Shane, Davis Kristina W, Elliott Audrea E, Wellman Paul J
Behavioral Neuroscience Program, Department of Psychology, Texas A&M University, College Station, TX 77843-4235, USA.
Life Sci. 2007 Sep 8;81(13):1059-65. doi: 10.1016/j.lfs.2007.08.004. Epub 2007 Aug 17.
Psychostimulants including amphetamine and cocaine induce locomotion and stereotypy and suppress eating. Although the capacity of cocaine to alter locomotion is usually viewed as related to dopamine neurotransmission, recent studies suggest that norepinephrine, acting through alpha1-adrenergic receptors (alpha1-ARs) can facilitate cocaine-stimulated locomotion. Of the three alpha1-AR subtypes (alpha(1A), alpha(1B), and alpha(1D)) identified to date, inactivation of the alpha(1B)-AR subtype diminishes cocaine-stimulated locomotion, whereas the impact of inactivation of the alpha(1A)-AR subtype on either eating or locomotion is unknown. In the present study, we assessed the relative impact of ICV administration of the alpha(1B)-AR antagonist 5-methylurapidil (5-MU) on cocaine-stimulated hyperlocomotion and hypophagia, using a concurrent method [Wellman, P.J., Ho, D.H., Davis, K.W., 2005. Concurrent measures of feeding and locomotion in rats. Physiology of Behavior 84 (5), 769-774.]. Rats were infused ICV with one of 3 doses of 5-MU (0, 3, or 30 nmol) and then injected (i.p.) with 0, 2.5, 5.0, 10.0, or 20.0 mg/kg cocaine HCl on each of five tests. Rats always received the same 5-MU dose, but a different cocaine dose on each trial. Feeding and locomotion were assessed concurrently during a 45-min postinjection period. Significant suppression of eating was noted at 2.5 mg/kg cocaine, a dose that does not alter forward locomotion in the rat. Administration of 5-MU did not alter locomotion in rats treated with saline, but did significantly increase baseline food intake. Neither cocaine-induced hypophagia nor hyperlocomotion was altered by ICV administration of 5-MU. These results suggest that the capacity of alpha1-AR agonists (e.g. phenylpropanolamine) to suppress eating may be related to activation of the alpha(1A)-AR subtype, whereas cocaine does not act through the alpha(1A)-AR subtype to suppress eating nor does this subtype modulate cocaine-induced hyperlocomotion.
包括苯丙胺和可卡因在内的精神兴奋剂会诱发运动和刻板行为,并抑制进食。虽然可卡因改变运动的能力通常被认为与多巴胺神经传递有关,但最近的研究表明,通过α1-肾上腺素能受体(α1-ARs)起作用的去甲肾上腺素可以促进可卡因刺激的运动。在迄今已鉴定出的三种α1-AR亚型(α(1A)、α(1B)和α(1D))中,α(1B)-AR亚型失活会减弱可卡因刺激的运动,而α(1A)-AR亚型失活对进食或运动的影响尚不清楚。在本研究中,我们使用一种并行方法[Wellman, P.J., Ho, D.H., Davis, K.W., 2005. 大鼠进食和运动的并行测量。行为生理学84 (5), 769 - 774.]评估了脑室内注射α(1B)-AR拮抗剂5-甲基乌拉地尔(5-MU)对可卡因刺激的运动亢进和摄食减少的相对影响。给大鼠脑室内注入3种剂量之一的5-MU(0、3或30 nmol),然后在5次测试中的每次测试中腹腔注射0、2.5、5.0、10.0或20.0 mg/kg的盐酸可卡因。大鼠每次总是接受相同的5-MU剂量,但每次试验接受不同的可卡因剂量。在注射后45分钟内同时评估进食和运动情况。在2.5 mg/kg可卡因剂量时观察到进食显著受到抑制,该剂量不会改变大鼠的向前运动。给予5-MU不会改变用生理盐水处理的大鼠的运动,但确实显著增加了基线食物摄入量。脑室内注射5-MU既不改变可卡因诱导的摄食减少,也不改变运动亢进。这些结果表明,α1-AR激动剂(如苯丙醇胺)抑制进食的能力可能与α(1A)-AR亚型的激活有关,而可卡因不是通过α(1A)-AR亚型来抑制进食的,该亚型也不调节可卡因诱导的运动亢进。